Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy.
Clinical and translational medicine（2023）
摘要
Our results suggest that pevonedistat synergises with carboplatin to inhibit RMC cell and tumour growth through inhibition of DNA damage repair. These findings support the development of a clinical trial combining pevonedistat with platinum-based chemotherapy for RMC.
更多查看译文
关键词
chemotherapy, neddylation, pevonedistat, renal medullary carcinoma
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要